Key Highlights
•
A new review links dysfunction in brain systems that control wakefulness (specifically involving norepinephrine, histamine, and orexin) to disrupted sleep and impaired clearance of toxic proteins in Alzheimer’s disease. This suggests that targeting these wake-promoting systems could be a new strategy to slow the disease by improving sleep and the brain’s natural cleaning process.
Source →
•
A framework for global surveillance highlights that amyloid-related imaging abnormalities (ARIA)—a side effect of new Alzheimer’s immunotherapies—are strongly linked to the APOE ε4 gene and pre-existing blood vessel damage in the brain. This underscores the critical need for careful genetic screening and MRI monitoring before and during treatment to improve patient safety.
Source →
•
A study in sheep shows that exposure to male hormones (androgens) during prenatal development can lead to long-term changes in sexual behavior in adulthood. This finding provides a crucial animal model for understanding how early hormone exposure might influence complex behaviors later in life.
Source →
•
Research finds that in patients without Alzheimer’s amyloid plaques, the severity of white matter damage in the brain is linked to reduced sugar metabolism in specific brain regions and worse cognitive performance. This highlights that factors other than amyloid, like blood vessel health, are major drivers of cognitive decline in a significant group of patients.
Source →
•
A European study of 162 patients finds that lung disease linked to a specific autoimmune condition (ANCA-associated vasculitis) often shows a severe scarring pattern on scans, and treatment with the drug rituximab may help preserve lung function. This emphasizes the importance of early diagnosis and personalized treatment for this serious complication.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
